Kyphoplasty Market (2026 - 2033)

Kyphoplasty Market Summary

The global kyphoplasty market size was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.0 billion by 2033, growing at a CAGR of 6.4% from 2026 to 2033. The North American market dominated, with a revenue share of over 50.0% in 2025. The growing elderly population and the rising prevalence of osteoporosis drive market growth. According to the International Osteoporosis Foundation, globally, 1 in 5 men and 1 in 3 women over the age of 50 are expected to experience osteoporosis-related fractures in their remaining years.

Vertebral compression fractures left untreated can have serious clinical consequences and significantly impact the quality of life of patients and caregivers. Since non-surgical management of these fractures has limited effectiveness, kyphoplasty procedures are gaining acceptance in medical practice for fracture stabilization and pain control.

The market is experiencing steady growth, driven by the increasing prevalence of vertebral compression fractures (VCFs), advancements in minimally invasive technologies, and expanding reimbursement support. According to the National Library of Medicine, approximately 1-1.5 million VCFs occur annually in the U.S. alone. Nearly 25% of women aged 50 years and older experience at least one VCF, while 40-50% of individuals over 80 years are estimated to have suffered a VCF, either diagnosed acutely or incidentally during treatment for other conditions. Vertebral augmentation procedures, including balloon kyphoplasty, have demonstrated significant clinical benefits.

Technological advancements and ongoing research initiatives continue to support market expansion. For instance, in October 2025, Stryker established an R&D laboratory in Queensland, Australia, to strengthen collaborations with researchers, hospitals, universities, and government organizations. The facility focuses on transforming research into commercially viable precision medical technologies across multiple divisions, including spine, trauma, joint replacement, and endoscopy.

Kyphoplasty procedures provide substantial clinical advantages, including pain relief, improved mobility, restoration of vertebral body height, and correction of spinal alignment. By reducing dependence on opioid medications and enhancing functional outcomes, these procedures significantly improve patients’ quality of life. Furthermore, kyphoplasty addresses complications associated with compression fractures, such as kyphotic deformity, reduced pulmonary capacity, and chronic pain.

Balloon kyphoplasty has been used for more than two decades to treat over one million vertebral fractures worldwide. Clinical evidence demonstrates its effectiveness in restoring vertebral body height, correcting spinal deformities, reducing back pain, and improving patients' mobility and daily functioning compared with conservative treatment approaches. In addition, advancements in clinically approved bone cements, including biodegradable and mechanically compatible formulations, are expanding treatment possibilities and enhancing patient outcomes. Coupled with the growing preference for minimally invasive procedures, these innovations continue to drive the global market.

Rising demand for minimally invasive orthopedic surgeries, increasing healthcare expenditure, and favorable reimbursement policies are further contributing to market growth. In September 2025, the SpineJack implantable fracture reduction system developed by Stryker received a New Technology Add-on Payment (NTAP) designation from the U.S. Centers for Medicare & Medicaid Services (CMS) under the inpatient prospective payment system, reinforcing reimbursement support for advanced spinal interventions.

Market Dynamics

Key factors, such as the rising prevalence of osteoporosis-induced VCFs, the increasing adoption of minimally invasive procedures in spine surgery, and greater awareness of the diagnosis and treatment of spine disorders, are driving global market growth. The growing elderly population prone to osteoporotic and spinal fractures remains a consistent contributor to the increasing demand for kyphoplasty procedures worldwide. Further enhancements in balloon kyphoplasty systems, bone cement materials, and image-guided spinal surgeries are leading to improved procedural outcomes and shorter patient recovery periods. The growing preference for ambulatory care surgery and the accessibility of advanced spine care in emerging markets are key market drivers.

Analyst Perspective

The market is becoming increasingly important as healthcare systems focus on improving mobility and quality of life for patients with spinal compression fractures. As aging populations grow, providers are placing greater emphasis on minimally invasive procedures that can reduce recovery time and hospital stays. Companies with strong clinical evidence, specialized expertise, and established relationships with hospitals and surgeons are likely to strengthen their market position. In the coming years, treatment decisions are expected to place greater weight on patient outcomes, procedural efficiency, and cost-effectiveness. As a result, providers that can demonstrate clear clinical benefits and support value-based care models are likely to gain a competitive advantage.

Product Insights

The bone access device segment accounted for the largest revenue share in 2025. In 2025, to meet the demand for real-time flow visualization during cement injection for kyphoplasty and vertebroplasty surgeries, IZI Medical Products introduced Vertefix HV cement. The company’s goal in this introduction was to provide doctors with a better way to monitor and manage cement flow during treatment.

Needles provide control & flexibility in accessing the vertebral body and delivering bone cement during vertebral compression fracture treatments. Globally, the prevalence of spine fractures and back pain is increasing exponentially. Around 2% of American laborers suffer compensable back injuries annually, accounting for around 500,000 cases. Low back pain accounts for 19% of all labor compensation claims in the U.S. Therefore, the prevalence of these conditions is expected to drive market growth.

The balloon catheters segment is expected to grow at the fastest CAGR during the forecast period, owing to technological advancements, including the advent of next-generation kyphoplasty balloons, which enable more efficient procedures. In addition, new product launches further contribute to market growth. For instance, Merit Medical Systems expanded its vertebral augmentation portfolio further in 2025 with its Arcadia Steerable and Straight Balloon Catheter, which aims to ensure selective cavity formation, restoration of vertebral height, and accurate cement delivery during the kyphoplasty procedure. Arcadia balloons featured prominently in the 2025 filings regarding its vertebral augmentation portfolio, indicating a significant industry trend toward developing novel balloon technologies to treat vertebral compression fractures.

Application Insights

The spinal fractures segment held the largest revenue share in 2025 and is expected to grow at the fastest CAGR over the forecast period, driven by the high adoption of kyphoplasty procedures for this application. Rising incidences of compressed spine bones due to cancer and trauma have led to the growth of the market. The bones of people with cancer and older people can break easily with little or no force, increasing the incidence of cases and increasing demand for kyphoplasty procedures.

Compression fractures affect many individuals worldwide. Vertebral compression fractures (VCFs) are the most common fracture in osteoporosis patients, affecting approximately 750,000 people annually. This condition gradually increases with age, with an estimated 40% of women aged 80 and older affected. Therefore, it supports overall market growth. For instance, in 2025, Amber Implants reported 1-year outcomes from its first-in-human clinical trial of the VCFix Spinal System for the management of vertebral compression fractures. The results showed substantial improvements in pain reduction, spinal stability, and function. This reflects the expanding development of new solutions for the management of spine fractures and the acceptance of vertebral augmentation.

End Use Insights

The hospital segment held the largest revenue share in 2025. Hospitals are the primary point of care for a wide range of health problems, so the segment is expected to hold the largest market share globally. Hospitals are an integral part of the healthcare industry and its primary revenue source, driving research and innovation. Consequently, numerous corporations are making significant efforts, both in terms of revenue & marketing strategies, to promote their products and services in hospitals.

The ambulatory surgical centers (ASC) segment is expected to grow at the fastest CAGR of 5.0% over the forecast period. An ambulatory surgery center offers a convenient alternative to hospitals, providing the same quality of care at a lower cost to individuals. Increased outpatient admissions can also be attributed to the growing adoption of advanced technologies in centers, which make treatment faster and more cost-effective. Innovative surgical methods in such settings allow tests and procedures to be performed without hospital admission. It is expected to support segment growth. For instance, in February 2025, SCA Health stated that its ambulatory surgery center and outpatient service network continue to grow across the U.S., driven by a broader shift toward lower-cost outpatient procedures. The expansion was expected to provide access to less-invasive spine treatments, including kyphoplasty.

Indication Insights

The osteoporosis segment held the largest revenue share in 2025. The increasing prevalence of osteoporosis can be attributed to the segment's large market share relative to other segments. Osteoporosis is a chronic bone illness characterized by low bone mineral density, reduced bone quality, and an increased susceptibility to fracture. Based on the findings of the National Osteoporosis Foundation, there is an increased risk for 44 million individuals in the U.S. who have insufficient bone density, and an estimated 10 million Americans are diagnosed with osteoporosis.

Furthermore, approximately 54 million people, constituting half of the adult population aged 50 and above, are at a heightened risk of bone fractures and should prioritize their bone health accordingly. Due to osteoporosis, one in two women and one in four men may break a bone during their lifetime. The prevalence is higher in women than for heart attack, stroke, and breast cancer combined.

The others segment is expected to grow at the fastest CAGR over the forecast period. Kyphoplasty is commonly used in the palliative treatment of metastatic vertebral tumors. From the perspective of aging patients in the U.S., kyphoplasty is more cost-effective than nonsurgical treatment. A study published in the National Library of Medicine found that the kyphoplasty procedure significantly and rapidly reduced pain intensity in cancer patients with VCFs. For instance, in April 2025, the International Osteoporosis Foundation launched awareness programs emphasizing the growing epidemic of fragility fractures and the importance of early diagnosis and treatment. These awareness programs are projected to result in higher screening rates for osteoporosis and thus, increase the diagnosis rate of vertebral compression fractures and create the demand for kyphoplasty procedures.

Regional Insights

North America dominated the market, accounting for over 50.0% of revenue in 2025, owing to high awareness levels and improved healthcare infrastructure. The dominance can be attributed to the rising prevalence of osteoporosis, back pain, and spine fractures. Over 54 million Americans have osteoporosis or low bone mass that places them at an increased risk for a fracture, reports the National Osteoporosis Foundation. Hip fractures from osteoporosis are common in post menopausal women. In fact, almost half of women 50 and older will have a fracture related to osteoporosis. This disease has been seen mostly in females in the region, compared with males. The surge in kyphoplasty adoption and the growing burden of vertebral compression fractures are driving market growth. Key companies such as Medtronic and Stryker are major revenue contributors and also undertake acquisitions and partnerships to drive market growth.

Asia Pacific Kyphoplasty Market Trends

The kyphoplasty market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period, driven by a growing patient pool and rising healthcare infrastructure. The aging population and growing acceptance of the procedure are driving market growth. Similarly, factors such as the availability of advanced fracture-stabilization methods, limitations of the conventional approach, the increasing incidence of vertebral compression fractures, rising cases of osteoporosis, improvements in health care infrastructure, and increased patient compliance due to technological advancements are among the other key aspects driving the Asia Pacific market.

Key Kyphoplasty Companies Insights

The key players are pursuing strategies such as new product development, distribution agreements, and expansion to improve their market penetration. For instance, in August 2025, IZI Medical introduced an Osteo-site Vertebral Balloon for vertebral augmentation. The novel Osteo-site Vertebral Balloon is intended to form a cavity within the vertebral body. This launch helped the company expand its product portfolio. Likewise, in June 2025, Joline GmbH & Co. KG received U.S. FDA approval for Joline Kyphoplasty products to treat vertebral compression fractures.

Key Kyphoplasty Companies

The following key companies have been profiled for this study on the kyphoplasty market.

• Stryker

• Medtronic Inc.

• Smith & Nephew

• MicroPort Scientific Corporation

• DePuy Synthes (Johnson & Johnson Services Inc.)

• IZI Medical Products

• CareFusion

• Merit Medical Systems

• Joimax GmbH

• G21 S.r.l.

• Joline GmbH & Co. KG

• Seawon Meditech

• Hensler Surgical Products

• Taeyeon Medical Co., Ltd.

• iMEDICOM

• Jiangsu ChangMei Medtech Co., Ltd.

Recent Developments

• In May 2025, Stryker received FDA clearance for its OptaBlate Basivertebral Nerve Ablation (BVN) system, a minimally invasive therapy for chronic vertebrogenic low back pain in the thoracic and lumbar spine associated with endplate damage. The addition of the vertebral access system to radiofrequency ablation expands the company’s interventional spine offerings and connects it to vertebrofracture and kyphoplasty adjacent procedures.

Kyphoplasty Market Report Scope

Global Kyphoplasty Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global kyphoplasty market report based on product, application, indication, end use, and region: 

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Balloon Catheters

  • Bone Access Devices

  • Cement Application Products

  • Bone Cement

  • Cement Mixing Systems

  • Instruments

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Vertebral Alignment Restoration

  • Spinal Fractures

  • Kyphosis

• Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Osteoporosis

  • Others

• End-Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals & Clinics

  • Ambulatory Surgical Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait